New Retinoic Acid and Clindamycin Products Developed with Invisicare(R)
LAS VEGAS, May 13 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) (http://www.skinvisible.com), a research and development company focused on formulating enhanced patented dermatology products, announced it has signed an exclusive licensing agreement with Embil Pharmaceutical Co. Ltd. ("Embil"). The Agreement is for the right to develop and market two of Skinvisible's prescription anti-acne products formulated with Invisicare and the active ingredients Clindamycin HCL, and Retinoic Acid. Invisicare is Skinvisible's patented polymer delivery technology that provides many benefits to topically delivered products including binding to the skin for four hours or more, resisting wash-off, decreased irritation and sustained release. Along with these benefits, Invisicare provides pharmaceutical companies with product life-cycle management for their branded products coming off patent by adding value and new patent protection.
This agreement with Embil, a multi-national dermatology company based in Istanbul, Turkey is Skinvisible's second entry into the $2.8 billion acne market. The territory includes Turkey, Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan, and Uzbekistan, as well as the S.E Asian countries of Indonesia, Malaysia, and the Philippines where Embil will seek marketing approval. This agreement, brought to Skinvisible by Riley-Nacht, LLC, one of our marketing partners, gives Embil the right to manufacture, distribute and market these acne formulations in a dual chamber device in the territory specified above. Skinvisible will receive a development fee, a license fee allocated in milestone payments as well as royalties based on product sales.
"Skinvisible has now formulated and licensed three key acne products; Adapalene, Clindamycin HCL and Retinoic Acid," said Mr. Terry Howlett, President / CEO of Skinvisible. "This new agreement shows that we continue to remain focused on our strategic plan to expand and license our patented product offerings around the world and we are very encouraged by the interest in these three acne products outside of the territories already signed."
Skinvisible is also seeking to license it's portfolio of over 25 topical dermatology products formulated with Invisicare including prescription and over-the-counter products for the treatment of atopic dermatitis, fungal infections, anti-inflammatories, as well as hand sanitizers, anti-aging, analgesic and sunscreen products.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com
Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. Other key benefits include its ability to gradually release active ingredients which reduces skin irritation and increases efficacy, it is non-occlusive on the skin and new patents can be issued for products formulated with Invisicare. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com
About Embil Pharmaceutical Co. Ltd.
Since 1945, Embil has been developing unique formulations for the Pharmaceutical Industry. In recent years, Embil's focus has been directed towards topical products for the treatment of acne and local pain management. Embil has a strong patent portfolio for Worldwide IP protection which enables Embil and its marketing partners to invest in new products for the future. Embil presently exports original pharmaceutical products to over 30 countries while new export territories are being added periodically.
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and are
subject to the safe harbors created thereby. Such statements involve
certain risks and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward looking
statements as a result of risk factors discussed in Skinvisible, Inc.
reports on file with the U.S. Securities and Exchange Commission
(including, but not limited to, a report on Form 10K for the year ending
December 31, 2007)
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc
|SOURCE Skinvisible, Inc.|
Copyright©2008 PR Newswire.
All rights reserved